LIVIVO - Search results -

Search results

Result 1 - 10 of total 46

Search options

Article ; Online: Mucosal immune responses to

Leach, Susannah

2020 Volume 16, Issue 10, Page(s) 2479–2480

MeSH term(s)	Antibody Formation ; Bangladesh ; Cholera/epidemiology ; Cholera/prevention & control ; Cholera Vaccines ; Humans ; Immunity, Mucosal ; O Antigens ; Vaccination ; Vibrio cholerae O1/immunology
Chemical Substances	Cholera Vaccines ; O Antigens
Language	English
Publishing date	2020-03-16
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	2664176-8
ISSN	2164-554X ; 2164-5515
ISSN (online)	2164-554X
ISSN	2164-5515
DOI	10.1080/21645515.2020.1729029
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6967: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Minst ett 70-tal möjliga vacciner mot sars-cov-2 är nu på gång.

Leach, Susannah

Lakartidningen

2020 Volume 117

Abstract: The development of vaccines against SARS-CoV-2 is progressing at an unparalleled speed. As of the 29th of March, there were at least 68 vaccine candidates comprising several different vaccine designs, including whole killed virus, subunit, attenuated, ... ...

Title translation	At least 68 vaccine candidates under development.
Abstract	The development of vaccines against SARS-CoV-2 is progressing at an unparalleled speed. As of the 29th of March, there were at least 68 vaccine candidates comprising several different vaccine designs, including whole killed virus, subunit, attenuated, viral vector, DNA and mRNA vaccines. Whilst it usually takes 10-15 years to develop a vaccine, it has only taken just over 9 weeks from the publication of the viral genetic sequence for the first vaccine candidate to reach clinical testing. Development has been expediated by using existing technological platforms and by performing preclinical and clinical testing simultaneously.
MeSH term(s)	Betacoronavirus/immunology ; COVID-19 ; COVID-19 Vaccines ; Coronavirus Infections/prevention & control ; Humans ; Pandemics/prevention & control ; Pneumonia, Viral/prevention & control ; SARS-CoV-2 ; Vaccines, DNA ; Viral Vaccines
Chemical Substances	COVID-19 Vaccines ; Vaccines, DNA ; Viral Vaccines
Keywords	covid19
Language	Swedish
Publishing date	2020-04-06
Publishing country	Sweden
Document type	Journal Article
ZDB-ID	391010-6
ISSN	1652-7518 ; 0023-7205
ISSN (online)	1652-7518
ISSN	0023-7205
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.411: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: [No title information]

Sjöberg, Sara / Leach, Susannah

Lakartidningen

2018 Volume 115

Abstract: MMR vaccination in 6-9 month olds Vaccination against measles using the MMR vaccine is licensed from 9 months of age, but is used off-label from 6 months of age during or when travelling to areas with an ongoing measles outbreak. In this review of the ... ...

Title translation	Mässlingsvaccin kan ges vid 6 månaders ålder i särskilda fall - Vid risk för smitta kan off label-användning övervägas, enligt en litteraturgenomgång.
Abstract	MMR vaccination in 6-9 month olds Vaccination against measles using the MMR vaccine is licensed from 9 months of age, but is used off-label from 6 months of age during or when travelling to areas with an ongoing measles outbreak. In this review of the published literature, studies on MMR vaccination in this age group are limited and small in size. Immunogenicity studies indicate that infants under 9 months respond with lower antibody titres but comparable T cell responses against measles. The safety profile of the vaccine does not appear to differ between infants vaccinated earlier or later. Vaccination from 6 months of age should be recommended if the risk of being infected with measles is considered greater than the risk of not attaining full vaccination protection.
MeSH term(s)	Age Factors ; Antibodies, Viral/blood ; Humans ; Immunization Schedule ; Infant ; Measles/prevention & control ; Measles-Mumps-Rubella Vaccine/adverse effects ; Measles-Mumps-Rubella Vaccine/pharmacology ; Measles-Mumps-Rubella Vaccine/therapeutic use ; Mumps/prevention & control ; Off-Label Use ; Practice Guidelines as Topic ; Rubella/prevention & control ; T-Lymphocytes/immunology
Chemical Substances	Antibodies, Viral ; Measles-Mumps-Rubella Vaccine
Language	Swedish
Publishing date	2018-01-15
Publishing country	Sweden
Document type	Journal Article
ZDB-ID	391010-6
ISSN	1652-7518 ; 0023-7205
ISSN (online)	1652-7518
ISSN	0023-7205
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.411: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Systems Biology Approach Identifies B Cell Maturation Antigen (BCMA) as a Biomarker Reflecting Oral Vaccine Induced IgA Antibody Responses in Humans.

Mottram, Lynda / Lundgren, Anna / Svennerholm, Ann-Mari / Leach, Susannah

Frontiers in immunology

2021 Volume 12, Page(s) 647873

Abstract: Vaccines against enteric diseases could improve global health. Despite this, only a few oral vaccines are currently available for human use. One way to facilitate such vaccine development could be to identify a practical and relatively low cost biomarker ...

Abstract	Vaccines against enteric diseases could improve global health. Despite this, only a few oral vaccines are currently available for human use. One way to facilitate such vaccine development could be to identify a practical and relatively low cost biomarker assay to assess oral vaccine induced primary and memory IgA immune responses in humans. Such an IgA biomarker assay could complement antigen-specific immune response measurements, enabling more oral vaccine candidates to be tested, whilst also reducing the work and costs associated with early oral vaccine development. With this in mind, we take a holistic systems biology approach to compare the transcriptional signatures of peripheral blood mononuclear cells isolated from volunteers, who following two oral priming doses with the oral cholera vaccine Dukoral®, had either strong or no vaccine specific IgA responses. Using this bioinformatical method, we identify
MeSH term(s)	Administration, Oral ; Adult ; B-Cell Maturation Antigen/genetics ; B-Lymphocytes/immunology ; Biomarkers ; Cells, Cultured ; Cholera/microbiology ; Cholera/prevention & control ; Cholera Vaccines/administration & dosage ; Cholera Vaccines/immunology ; Enterotoxigenic Escherichia coli/immunology ; Escherichia coli Infections/microbiology ; Escherichia coli Infections/prevention & control ; Escherichia coli Vaccines/administration & dosage ; Escherichia coli Vaccines/immunology ; Healthy Volunteers ; Humans ; Immunity, Humoral/genetics ; Immunoglobulin A/immunology ; Immunologic Memory ; Systems Biology/methods ; Transcriptome ; Vaccination/methods ; Vibrio cholerae/immunology
Chemical Substances	B-Cell Maturation Antigen ; Biomarkers ; Cholera Vaccines ; Dukoral ; Escherichia coli Vaccines ; Immunoglobulin A ; TNFRSF17 protein, human
Language	English
Publishing date	2021-03-22
Publishing country	Switzerland
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2021.647873
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: COVID-19 Outcomes and Vaccinations in Swedish Solid Organ Transplant Recipients 2020-2021: A Nationwide Multi-Register Comparative Cohort Study.

Søfteland, John Mackay / Li, Huiqi / Magnusson, Jesper M / Leach, Susannah / Friman, Vanda / Gisslén, Magnus / Felldin, Marie / Schult, Andreas / Karason, Kristjan / Baid-Agrawal, Seema / Wallquist, Carin / Nyberg, Fredrik

Viruses

2024 Volume 16, Issue 2

Abstract: Increased COVID-19-related morbidity and mortality have been reported in solid organ transplant recipients (SOTRs). Most studies are underpowered for rigorous matching. We report infections, hospitalization, ICU care, mortality from COVID-19, and ... ...

Abstract	Increased COVID-19-related morbidity and mortality have been reported in solid organ transplant recipients (SOTRs). Most studies are underpowered for rigorous matching. We report infections, hospitalization, ICU care, mortality from COVID-19, and pertinent vaccination data in Swedish SOTRs 2020-2021. We conducted a nationwide cohort study, encompassing all Swedish residents. SOTRs were identified with ICD-10 codes and immunosuppressant prescriptions. Comparison cohorts were weighted based on a propensity score built from potential confounders (age, sex, comorbidities, socioeconomic factors, and geography), which achieved a good balance between SOTRs and non-SOTR groups. We included 10,372,033 individuals, including 9073 SOTRs. Of the SARS-CoV-2 infected, 47.3% of SOTRs and 19% of weighted comparator individuals were hospitalized. ICU care was given to 8% of infected SOTRs and 2% of weighted comparators. The case fatality rate was 7.7% in SOTRs, 6.2% in the weighted comparison cohort, and 1.3% in the unweighted comparison cohort. SOTRs had an increased risk of contracting COVID-19 (HR = 1.15
MeSH term(s)	Humans ; Cohort Studies ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19/etiology ; Sweden/epidemiology ; Transplant Recipients ; Organ Transplantation/adverse effects ; SARS-CoV-2 ; Vaccination
Language	English
Publishing date	2024-02-08
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v16020271
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Author Correction: Plant-microbiome interactions: from community assembly to plant health.

Trivedi, Pankaj / Leach, Jan E / Tringe, Susannah G / Sa, Tongmin / Singh, Brajesh K

Nature reviews. Microbiology

2020 Volume 19, Issue 1, Page(s) 72

Language	English
Publishing date	2020-11-07
Publishing country	England
Document type	Published Erratum
ZDB-ID	2139054-X
ISSN	1740-1534 ; 1740-1526
ISSN (online)	1740-1534
ISSN	1740-1526
DOI	10.1038/s41579-020-00490-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5865: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 74: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study.

Dahlén, Torsten / Flygt, Hjalmar / Lübking, Anna / Olsson-Strömberg, Ulla / Wennström, Lovisa / Dreimane, Arta / Själander, Anders / Leach, Susannah / Gisslén, Magnus / Li, Huiqi / Höglund, Martin / Stenke, Leif / Nyberg, Fredrik

Leukemia

2023 Volume 37, Issue 5, Page(s) 1156–1159

MeSH term(s)	Humans ; COVID-19/epidemiology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology ; Leukemia, Myeloid ; Chronic Disease
Language	English
Publishing date	2023-04-10
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	807030-1
ISSN	1476-5551 ; 0887-6924
ISSN (online)	1476-5551
ISSN	0887-6924
DOI	10.1038/s41375-023-01893-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2295: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study.

Lundberg-Morris, Lisa / Leach, Susannah / Xu, Yiyi / Martikainen, Jari / Santosa, Ailiana / Gisslén, Magnus / Li, Huiqi / Nyberg, Fredrik / Bygdell, Maria

BMJ (Clinical research ed.)

2023 Volume 383, Page(s) e076990

Abstract: Objective: To investigate the effectiveness of primary covid-19 vaccination (first two doses and first booster dose within the recommended schedule) against post-covid-19 condition (PCC).: Design: Population based cohort study.: Setting: Swedish ... ...

Abstract	Objective: To investigate the effectiveness of primary covid-19 vaccination (first two doses and first booster dose within the recommended schedule) against post-covid-19 condition (PCC). Design: Population based cohort study. Setting: Swedish Covid-19 Investigation for Future Insights-a Population Epidemiology Approach using Register Linkage (SCIFI-PEARL) project, a register based cohort study in Sweden. Participants: All adults (≥18 years) with covid-19 first registered between 27 December 2020 and 9 February 2022 (n=589 722) in the two largest regions of Sweden. Individuals were followed from a first infection until death, emigration, vaccination, reinfection, a PCC diagnosis (ICD-10 diagnosis code U09.9), or end of follow-up (30 November 2022), whichever came first. Individuals who had received at least one dose of a covid-19 vaccine before infection were considered vaccinated. Main outcome measure: The primary outcome was a clinical diagnosis of PCC. Vaccine effectiveness against PCC was estimated using Cox regressions adjusted for age, sex, comorbidities (diabetes and cardiovascular, respiratory, and psychiatric disease), number of healthcare contacts during 2019, socioeconomic factors, and dominant virus variant at time of infection. Results: Of 299 692 vaccinated individuals with covid-19, 1201 (0.4%) had a diagnosis of PCC during follow-up, compared with 4118 (1.4%) of 290 030 unvaccinated individuals. Covid-19 vaccination with any number of doses before infection was associated with a reduced risk of PCC (adjusted hazard ratio 0.42, 95% confidence interval 0.38 to 0.46), with a vaccine effectiveness of 58%. Of the vaccinated individuals, 21 111 received one dose only, 205 650 received two doses, and 72 931 received three or more doses. Vaccine effectiveness against PCC for one dose, two doses, and three or more doses was 21%, 59%, and 73%, respectively. Conclusions: The results of this study suggest a strong association between covid-19 vaccination before infection and reduced risk of receiving a diagnosis of PCC. The findings highlight the importance of primary vaccination against covid-19 to reduce the population burden of PCC.
MeSH term(s)	Adult ; Humans ; COVID-19 Vaccines ; COVID-19/epidemiology ; COVID-19/prevention & control ; Sweden/epidemiology ; Cohort Studies ; Vaccine Efficacy
Chemical Substances	COVID-19 Vaccines
Language	English
Publishing date	2023-11-22
Publishing country	England
Document type	Journal Article
ZDB-ID	1362901-3
ISSN	1756-1833 ; 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
ISSN (online)	1756-1833
ISSN	0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
DOI	10.1136/bmj-2023-076990
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Mucosal Immune Responses Against an Oral Enterotoxigenic Escherichia coli Vaccine Evaluated in Clinical Trials.

Svennerholm, Ann-Mari / Lundgren, Anna / Leach, Susannah / Akhtar, Marjahan / Qadri, Firdausi

The Journal of infectious diseases

2021 Volume 224, Issue 12 Suppl 2, Page(s) S821–S828

Abstract: Enterotoxigenic Escherichia coli (ETEC) is a leading cause of mortality and morbidity in children in low-income countries. We have tested an oral ETEC vaccine, ETVAX, consisting of inactivated E coli overexpressing the most prevalent colonization factors ...

Abstract	Enterotoxigenic Escherichia coli (ETEC) is a leading cause of mortality and morbidity in children in low-income countries. We have tested an oral ETEC vaccine, ETVAX, consisting of inactivated E coli overexpressing the most prevalent colonization factors and a toxoid, LCTBA, administered together with a mucosal adjuvant, double-mutant heat-labile toxin (dmLT), for capacity to induce mucosal immune responses and immunological memory against the primary vaccine antigens, ie, colonization factors, heat-labile toxin B-subunit and O antigen. The studies show that ETVAX could induce strong intestine-derived and/or fecal immune responses in a majority of vaccinated Swedish adults and in different age groups, including infants, in Bangladesh.
MeSH term(s)	Adolescent ; Adult ; Antibodies, Bacterial ; Child ; Enterotoxigenic Escherichia coli/immunology ; Enterotoxins ; Escherichia coli Infections/prevention & control ; Escherichia coli Proteins ; Escherichia coli Vaccines/administration & dosage ; Humans ; Immunity, Mucosal ; Infant ; Middle Aged
Chemical Substances	Antibodies, Bacterial ; Enterotoxins ; Escherichia coli Proteins ; Escherichia coli Vaccines
Language	English
Publishing date	2021-09-22
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	3019-3
ISSN	1537-6613 ; 0022-1899
ISSN (online)	1537-6613
ISSN	0022-1899
DOI	10.1093/infdis/jiab475
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh II Zs.50: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 445: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not.

Beck-Friis, Josefine / Leach, Susannah / Omerovic, Elmir / Zeijlon, Rickard / Gisslen, Magnus / Yilmaz, Aylin

PloS one

2021 Volume 16, Issue 8, Page(s) e0256035

Abstract: Background: Chloroquine was promoted as a COVID-19 therapeutic early in the pandemic. Most countries have since discontinued the use of chloroquine due to lack of evidence of any benefit and the risk of severe adverse events. The primary aim of this ... ...

Abstract	Background: Chloroquine was promoted as a COVID-19 therapeutic early in the pandemic. Most countries have since discontinued the use of chloroquine due to lack of evidence of any benefit and the risk of severe adverse events. The primary aim of this study was to examine if administering chloroquine during COVID-19 imposed an increased risk of ischemic heart injury or heart failure. Methods: Medical records, laboratory findings, and electrocardiograms of patients with COVID-19 who were treated with 500 mg chloroquine phosphate daily and controls not treated with chloroquine were reviewed retrospectively. Controls were matched in age and severity of disease. Results: We included 20 patients receiving chloroquine (500 mg twice daily) for an average of five days, and 40 controls. The groups were comparable regarding demographics and biochemical analyses including C-reactive protein, thrombocytes, and creatinine. There were no statistically significant differences in cardiac biomarkers or in electrocardiograms. Median troponin T was 10,8 ng/L in the study group and 17.9 ng/L in the control group, whereas median NT-proBNP was 399 ng/L in patients receiving chloroquine and 349 ng/L in the controls. Conclusions: We found no increased risk of ischemic heart injury or heart failure as a result of administering chloroquine. However, the use of chloroquine to treat COVID-19 outside of clinical trials is not recommended, considering the lack of evidence of its effectiveness, as well as the elevated risk of fatal arrythmias.
MeSH term(s)	Aged ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Biomarkers/analysis ; C-Reactive Protein/analysis ; COVID-19/drug therapy ; COVID-19/pathology ; COVID-19/virology ; Case-Control Studies ; Chloroquine/adverse effects ; Chloroquine/analogs & derivatives ; Chloroquine/therapeutic use ; Creatinine/analysis ; Electrocardiography ; Female ; Heart Failure/etiology ; Heart Failure/metabolism ; Heart Injuries/etiology ; Heart Injuries/metabolism ; Humans ; Male ; Middle Aged ; Natriuretic Peptide, Brain/analysis ; Peptide Fragments/analysis ; Retrospective Studies ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Troponin T/analysis
Chemical Substances	Antiviral Agents ; Biomarkers ; Peptide Fragments ; Troponin T ; pro-brain natriuretic peptide (1-76) ; Natriuretic Peptide, Brain (114471-18-0) ; chloroquine diphosphate (6E17K3343P) ; Chloroquine (886U3H6UFF) ; C-Reactive Protein (9007-41-4) ; Creatinine (AYI8EX34EU)
Language	English
Publishing date	2021-08-16
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0256035
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED